Published in Ther Adv Urol on November 30, 2015
Androgen-Deprivation Therapy and Cardiovascular Disease Risk - The Role of Exercise in Prostate Cancer Treatment. Front Oncol (2016) 0.75
Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Curr Treat Options Cardiovasc Med (2017) 0.75
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Pathophysiology of coronary artery disease. Circulation (2005) 6.65
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J (2008) 4.74
Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med (2010) 4.52
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol (2013) 3.74
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res (2008) 3.71
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia (1991) 3.48
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol (2014) 2.76
Macrophage plasticity in experimental atherosclerosis. PLoS One (2010) 2.75
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation (1995) 2.29
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Update on acute coronary syndromes: the pathologists' view. Eur Heart J (2012) 2.10
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2015) 1.98
Mechanisms of plaque formation and rupture. Circ Res (2014) 1.98
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol (2013) 1.74
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol (2014) 1.63
Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation (1999) 1.58
Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol (Oxf) (2012) 1.53
Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation (2004) 1.43
Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol (2001) 1.42
Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol (2011) 1.37
Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation (2005) 1.32
Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A (2001) 1.30
Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation (1999) 1.27
Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. Endocrinology (2003) 1.18
Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol (2004) 1.18
Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol (1999) 1.17
The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol (2014) 1.14
Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol (2008) 1.12
Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun (2002) 1.12
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol (2014) 1.09
Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) (2011) 1.08
Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol (1985) (2001) 1.05
Obesity and dyslipidemia. Med Clin North Am (2011) 1.05
Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol (2012) 1.04
Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol (2010) 1.02
Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab (1999) 1.02
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol (2005) 1.00
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism (1987) 1.00
Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology (2010) 0.99
Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res (2007) 0.99
Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation (2007) 0.98
Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. J Am Coll Cardiol (2003) 0.96
Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One (2015) 0.95
Macrophage phenotypes and their modulation in atherosclerosis. Circ J (2014) 0.95
Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci U S A (2002) 0.95
Possible role of Ca2+ channels in the vasodilating effect of 5beta-dihydrotestosterone in rat aorta. Eur J Pharmacol (1999) 0.95
GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol (2014) 0.93
Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids (2013) 0.93
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer (2013) 0.92
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res (2006) 0.91
Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett (2002) 0.90
Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology (2010) 0.90
Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol (2007) 0.90
Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol (2011) 0.89
Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One (2014) 0.88
Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol (2012) 0.87
GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol (2005) 0.87
Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab (1985) 0.83
Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets. Steroids (2007) 0.83
Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol. Steroids (2012) 0.82
Testosterone and estradiol modulate TNF-alpha-induced expression of adhesion molecules in endothelial cells. Methods Find Exp Clin Pharmacol (2002) 0.82
Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. J Am Heart Assoc (2015) 0.81
Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis. Diabetes (2012) 0.81
Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl (2009) 0.81
Modulation of neointimal lesion formation by endogenous androgens is independent of vascular androgen receptor. Cardiovasc Res (2014) 0.80
New therapy via targeting androgen receptor in monocytes/macrophages to battle atherosclerosis. Hypertension (2014) 0.80
Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer (2014) 0.80
Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population. J Diabetes (2014) 0.79
Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol (Oxf) (1994) 0.78
Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers. Urology (2013) 0.77
FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway. Aging Cell (2015) 0.76
Endogenous testosterone increases leukocyte-endothelial cell interaction in spontaneously hypertensive rats. Life Sci (2012) 0.76
Testosterone relaxes abdominal aorta in male Sprague-Dawley rats by opening potassium (K(+)) channel and blockade of calcium (Ca(2+)) channel. Pathophysiology (2011) 0.75
Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma. J Endocrinol Invest (1987) 0.75